湖南医保目录114种新药纳入，肿瘤、罕见病保障再突破

Core Insights - The new drug directory includes 114 newly added drugs, focusing on key areas such as cancer and rare diseases, complementing the basic medical insurance directory [1][2] - The implementation of the updated drug directory will take effect on January 1, 2026, and will be valid until December 31, 2026 [1] Group 1: National Drug Directory Adjustments - A total of 114 drugs have been added to the national directory, with 29 drugs removed; the updated directory now includes 3,253 drugs [2] - Among the newly added drugs, 111 are new products launched within the last five years, with 36 being cancer medications and 10 for rare diseases, enhancing coverage for critical areas [2] - A six-month transition period will be provided for drugs that were removed from the negotiation list to ensure continuity of medication [2] Group 2: Commercial Health Insurance Innovation - The first version of the commercial health insurance innovation drug directory includes 19 drugs, focusing on high-value innovative treatments not fully covered by basic medical insurance [3] - The directory features 9 new drugs and includes 5 CAR-T products, highlighting significant advancements in treatment options [3] - The commercial insurance directory serves as a reference for insurance companies and does not guarantee reimbursement, as it depends on the specific insurance policy [3] Group 3: Payment Standards and Drug Access - The Hunan Provincial Medical Insurance Bureau has established self-payment ratios for the new drug directory, with Class A drugs having a self-payment ratio of 0% [4] - The province aims to facilitate the inclusion of new drugs in hospitals and has mandated local medical insurance departments to guide medical institutions in the proper use of listed drugs [4] - The payment for work-related injury and maternity insurance will not differentiate between Class A and Class B drugs, covering the full cost [4]